ANDA 76007, held by Sun Pharmaceutical Industries. Hydrochlorothiazide; Lisinopril.
As of Nov 21, 2026, ANDA 76007 (Lisinopril and Hydrochlorothiazide), held by Sun Pharmaceutical Industries, was first approved by FDA on Jul 1, 2002, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2002 | Original application | Approved |
| Lisinopril and Hydrochlorothiazide12.5MG;10MG ยท tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide12.5MG;20MG ยท tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide25MG;20MG ยท tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Feb 28, 2014 | Supplement 16Labeling ยท Standard review | Approved | None posted |
| Aug 5, 2013 | Supplement 12Labeling ยท Standard review | Approved | None posted |
| Aug 5, 2013 | Supplement 13Labeling ยท Standard review | Approved | None posted |
| Aug 5, 2013 | Supplement 14Labeling ยท Standard review | Approved | None posted |
| Aug 5, 2013 | Supplement 15Labeling ยท Standard review | Approved | None posted |
| Sep 2, 2009 | Supplement 10Labeling | Approved | None posted |
| Jul 1, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters